HANGZHOU and SHAOXING, China, Sept. 25, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today thatGanovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program ("Pilot Program") for outpatients with hepatitis C. The Pilot Program supports hepatitis
Ganovo® is the first DAA developed and commercialized by a domestic company in China. Ganovo® inhibits the hepatitis C virus (HCV) NS3/4A protease that is critical to HCV replication. In the phase III clinical trial conducted in Mainland China, Ganovo regimen (Ganovo® in combination with PEGylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in genotype 1 non-cirrhotic patients, with a 12-week treatment duration.
"Thanks to the Tianjin Medical Insurance Authority and clinical community for their support to domestically developed innovative drugs. The reimbursement reflects the clinical experts' endorsement of Ganovo's efficacy and safety, as well as the government's support for innovative drugs and care for patients," said Jinzi J. Wu, Ph.D., Ascletis' founder, Chairman and CEO. "The Pilot Program fulfilled the concept of value-based payment. Starting from Tianjin, we anticipate Ganovo® will gain reimbursement access in more provinces and benefit more hepatitis C patients in China."
View original content:http://www.prnewswire.com/news-releases/ganovo-enrolled-in-the-basic-medical-insurance-of-tianjin--capped-reimbursement-per-patient-pilot-program-300718519.html
SOURCE Ascletis Pharma Inc.
Subscribe to our Free Newsletters!